Most studies rely on transgenic models such as APP/PS1, which do not recapitulate environmental exposures or genetic heterogeneity in sporadic AD, and there is limited evaluation of blood–brain barrier penetration or cognitive benefit for ferroptosis inhibitors such as CuII(atsm). Here, PSEN1 is linked to Alzheimer disease.